Version 1
: Received: 15 March 2024 / Approved: 18 March 2024 / Online: 18 March 2024 (11:24:43 CET)
How to cite:
Niazi, S. K.; Magoola, M. Universal mRNA-based HIV Vaccine for Acute and Latent Infections. Preprints2024, 2024031035. https://doi.org/10.20944/preprints202403.1035.v1
Niazi, S. K.; Magoola, M. Universal mRNA-based HIV Vaccine for Acute and Latent Infections. Preprints 2024, 2024031035. https://doi.org/10.20944/preprints202403.1035.v1
Niazi, S. K.; Magoola, M. Universal mRNA-based HIV Vaccine for Acute and Latent Infections. Preprints2024, 2024031035. https://doi.org/10.20944/preprints202403.1035.v1
APA Style
Niazi, S. K., & Magoola, M. (2024). Universal mRNA-based HIV Vaccine for Acute and Latent Infections. Preprints. https://doi.org/10.20944/preprints202403.1035.v1
Chicago/Turabian Style
Niazi, S. K. and Matthias Magoola. 2024 "Universal mRNA-based HIV Vaccine for Acute and Latent Infections" Preprints. https://doi.org/10.20944/preprints202403.1035.v1
Abstract
Human Immunodeficiency Virus (HIV) infection and its latent recurrent infection make vaccine development a significant challenge for traditional vaccines; however, the mRNA delivery of multiepitope antigens capable of creating antibodies against the surface proteins of HIV-1 and HIV-2 along with their respective Nef proteins, responsible for the latent infection can bring a most effective, as well as affordable solution to the unresolved epidemics of HIV. In this paper, we present the complete design of a multiepitope vaccine to prevent acute infections and inactivate Nef proteins that block the MHC-1 and MHC-2 pathways to hide the virus for later reinfection.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.